Instructor and Guest Lecturer Bios
From Cyberlaw
Contents |
Professors
Charles Nesson
Charles R. Nesson (nesson@law.harvard.edu) is William F. Weld Professor of Law at Harvard Law School, an affiliated faculty member of the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics, and faculty co-director of Harvard's Berkman Center for the Internet & Society, a research program which he founded to explore the implications of cyberspace, share in its study, and help pioneer its development. In 2004, Professor Nesson served as moderator for the Biotechnology Industry Organization's roundtable, where a group of leading academic and industry representatives explored the role of ethics in biotechnology drug pricing. Professor Nesson is a graduate of Harvard College and Harvard Law School.
Bruce Leicher
Bruce A. Leicher (bleicher@Antigenics.com) is Vice President and General Counsel at Antigenics, Inc., a Lexington, Massachusetts biotechnology company which is developing patient-specific immuno-therapeutics and treatments for cancers, infectious diseases and autoimmune disorders. Prior to joining Antigenics, Mr. Leicher was vice president, chief pharmaceutical counsel and compliance officer at Millennium Pharmaceuticals. While at Millennium, he was a leader in the creation of the commercial infrastructure to launch Velcade (bortezomib) — the first proteasome inhibitor approved by the US Food and Drug Administration — as a treatment for multiple myeloma. Prior to joining Millennium, he was co-chair of the life sciences practice group at Hill & Barlow in Boston. He also served as vice president and general counsel at Curis Inc., and vice president-law at Genetics Institute, Inc.
With 25 years of legal experience, Mr. Leicher has developed a specific expertise in implementing systems that facilitate accelerated product development and compliance with US and international regulatory requirements. He has also built and managed legal teams; trained clinical and R&D operations professionals to handle high-volume research and clinical contracts; participated in portfolio and strategic planning; and managed significant product partnering and acquisition transactions. Mr. Leicher received a bachelor’s degree in psychology from the University of Rochester in New York, and a law degree from Georgetown University Law Center.
Gary A. Cohen
Gary A. Cohen (gacbos@comcast.net) has nearly 20 years of legal experience, including representation of industry-leading biotechnology companies. Mr. Cohen's expertise includes the development and management of corporate law departments, and the benefits – and challenges – of using the law and lawyers to build ethical corporate cultures. Mr. Cohen's longstanding interest in law, science and public policy, and his experiences as corporate counsel, lead to an evolving career in bioethics and business ethics. Until late 2005, Mr. Cohen was Vice President, Ethics & Corporate Responsibility at Millennium Pharmaceuticals, Inc., one of the world's most prominent biopharmaceutical companies. Mr. Cohen's expertise in "bioindustry ethics," and his advocacy for responsible corporate decision-making and behavior, propelled Millennium to a leadership role in industry – "Millennium is arguably the leading advocate for ethics within biotechnology," the authors of a recent casebook concluded.
When Mr. Cohen joined Millennium in 1998, he was the company's first in-house corporate lawyer. By the time he assumed responsibility for the company's new ethics function, Mr. Cohen had helped Millennium build one of the strongest corporate, transactional and intellectual property law departments in the industry. Prior to joining Millennium, Mr. Cohen was vice president and general counsel at Genzyme Transgenics Corporation (now GTC BioTherapeutics, Inc.), and senior counsel at Genetics Institute, Inc. Earlier in his career, he was a business and international law attorney at Palmer & Dodge, and a resident foreign legal advisor to the Yuasa and Hara law firm in Tokyo. Mr. Cohen received a bachelor’s degree from Washington University in St. Louis (1982) and a law degree from Columbia University (1986). He has studied at the Beijing Language Institute (1982-1983) and will complete an MPH degree in health law, bioethics and human rights at the Boston University School of Public Health in May, 2006.
Guest Lecturers
George Annas
George Annas is the Edward R. Utley Professor and Chair of the Department of Health Law, Bioethics & Human Rights of Boston University School of Public Health, and Professor in the Boston University School of Medicine, and School of Law. He is the cofounder of Global Lawyers and Physicians, a transnational professional association of lawyers and physicians working together to promote human rights and health. He has degrees from Harvard College (A.B. economics, '67), Harvard Law School (J.D. '70) and Harvard School of Public Health (M.P.H. '72), where he was a Joseph P. Kennedy Fellow in Medical Ethics. After graduating from law school, he clerked for Justice John V. Spalding of the Massachusetts Supreme Judicial Court, and came to Boston University in 1972 as the Director of the Center for Law and Health Sciences at the law school. At Boston University he has taught graduate courses at the School of Public Health, Medical School, and Law School that have included Health Law; Human Experimentation; American Bioethics; Health and Human Rights; Advanced Topics in Health Law; Law, Medicine & Literature; Genetics and the Law; Patient Rights; and Health Law, Bioethics & Human Rights. Professor Annas has authored, coauthored, or co-edited 16 books, including The Rights of Patients, initially published in 1975 but now in its 3rd edition (NYU Press, 2004), American Bioethics: Crossing Human Rights and Health Law Boundaries (Oxford U. Press, 2005), Some Choice: Law, Medicine, and the Market (Oxford U. Press, 1999), Standard of Care: The Law of American Bioethics (Oxford U. Press, 1993), and Judging Medicine (Humana Press, 1987). Since 199l he has written the “Legal Issues in Medicine” feature for the New England Journal of Medicine.
T. Forcht Dagi
T. Forcht (Teo) Dagi is Managing Partner of Cordova Technologies, a venture capital firm based in Atlanta. From 1995 to 1996, he served as director and principal of Access Partners, and early stage biotechnology fund in Westport, Connecticut. Prior to 1995, Dr. Dagi advised venture groups and financial institutions on investments in health care services and health care technologies. Dr. Dagi received an AB from Columbia College; an MD and MPH from Johns Hopkins; an MTS from Harvard, where he was appointed Joseph P. Kennedy, Jr., Fellow; and an MBA in finance and strategic planning from the Wharton School of the University of Pennsylvania. He was trained in neurosurgery and neurophysiology at the Massachusetts General Hospital and Harvard Medical School, where he was a Neuroresearch Foundation Fellow, and served as Senior Registrar at the Neurosurgical Unit of the Guy’s, Maudsley and King’s College Hospitals, London. He is a Diplomat of the American Board of Neurological Surgeons and a Fellow of both the American College of Surgeons and the College of Critical Care Medicine. Dr. Dagi has taught at Harvard University, Georgetown University, and Brown University, where he was appointed to the Weyland Collegium. He currently serves as Clinical Professor of Surgery at the Medical College of Georgia, and Visiting Professor of Management at the Georgia Institute of Technology. Dr. Dagi serves as a director of several privately and publicly held corporations in the areas of biotechnology, medical devices, and healthcare and information technology. He is a director of the American Association of Neurological Surgery, the Georgia Neurosurgical Society, and the Harvard Club of Georgia, and sits on the board of advisors of the Wharton School of the University of Pennsylvania, and the DuPree College of Management of the Georgia Institute of Technology.
Sheldon Krimsky
Sheldon Krimsky is professor of Urban & Environmental Policy & Planning at Tufts University. He received his bachelors and masters degrees in physics from Brooklyn College, CUNY and Purdue University respectively, and a masters and doctorate in philosophy at Boston University. Professor Krimsky's research has focused on the linkages between science/technology, ethics/values and public policy. He is the author of eight books: Genetic Alchemy: The Social History of the Recombinant DNA Controversy (MIT Press) 1982, Biotechnics and Society: The Rise of Industrial Genetics (Praeger) 1991, Hormonal Chaos: The Scientific and Social Origins of the Environmental Endocrine Hypothesis(Johns Hopkins University Press, 2000), Science in the Private Interest: Has the lure of profits corrupted biomedical research? (Rowman & Littlefield Pub.) 2003. He is co-author of Environmental Hazards: Communicating Risks as a Social Process (Auburn House) 1988 and Agricultural Biotechnology and the Environment: Science, Policy and Social Values (University of Illinois), 1996 and co-editor of a collection of papers titled Social Theories of Risk (Praeger) 1992. Professor Krimsky has published over 150 essays and reviews that have appeared in many books and journals. His current book is a co-edited volume titled Rights and Liberties in the Biotech Age: Why We Need a Genetic Bill of Rights (Rowman & Littlefield Pub.) 2005. Professor Krimsky served on the National Institutes of Health's Recombinant DNA Advisory Committee from 1978-1981. He was a consultant to the Presidential Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research and to the Congressional Office of Technology Assessment. He participated on a special study panel for the American Civil Liberties Union that formulated a policy on civil liberties and scientific research. Professor Krimsky was chairperson of the Committee on Scientific Freedom and Responsibility for the American Association for the Advancement of Science for 1988-1992. Currently he serves on the Board of Directors for the Council for Responsible Genetics and as a Fellow of the Hastings Center on Bioethics.
Beverly Lorell, M.D.
Beverly Lorell, M.D. is vice president, chief medical and technology officer at the medical device company, Guidant. In this role, Dr. Lorell is responsible for evaluating new and emerging technologies, determining product development priorities, and influencing the company's clinical research strategy across all of its businesses. Dr. Lorell is a member of Guidant's "Compass Board" – the company's venture investing and business development group that looks at emerging therapies and their potential to improve patient care. In addition to her role at Guidant, Dr. Lorell is Professor of Medicine at Harvard University Medical School. Previously, Dr. Lorell served as director, Program in Heart Failure at Beth Israel Deaconess Medical Center. She also served as a member of Beth Israel's interventional cardiology team. Dr. Lorell is internationally recognized for her expertise in clinical care of heart failure as well as cardiac catheterization - interventional cardiology. She is also an expert in diagnosis and care of patients with coronary artery disease and acute ischemic syndromes. During her 20 years as a senior faculty member at Beth Israel Hospital and Beth Israel Deaconess Medical Center, she has conducted extensive research in the treatment of patients with advanced heart failure. She has also led a basic science research team which focused on discovery of mechanisms of cardiac protection in heart failure and ischemic heart disease. Her work has been published extensively and she has served as an invited lecturer at various heart conferences and symposiums around the world. Dr. Lorell has served in leadership positions on numerous national advisory boards and committees, including the American Heart Association, Heart Failure Society of America and American College of Cardiology, which guide national standards for care of heart failure patients. She has served as advisor to the federal government in major leadership roles, including service on study section of the National Institutes of Health as well as the Cardiovascular and Renal Drugs Advisory Committee of the FDA. Dr. Lorell received a bachelor of arts with distinction from Stanford University in 1971, and earned her medical doctorate from Stanford University School of Medicine in 1975. She served as a medical intern and resident physician at Stanford University Hospital, and completed clinical and research fellowships in cardiology at Massachusetts General Hospital and Harvard Medical School.
Scott A. Brown
Scott A. Brown is Vice President and Deputy General Counsel at Millennium Pharmaceuticals, Inc, where he oversees development and implementation of Millennium's intellectual property and licensing strategy, including procurement of patents, review of intellectual property aspects of company transactions and analysis of intellectual property issues relating to Millennium's activities. Prior to joining Millennium, Mr. Brown was Senior Patent Counsel at Genetics Institute, Inc. and an attorney with the firms of Kenyon & Kenyon and Dorsey & Whitney. Mr. Brown has presented at numerous industry and intellectual property law symposia, and is co-author (with course instructor Gary Cohen and others) of "Genetic Patent Protection in the Pharmaceutical and Biotechnology Industries," Community Genetics (2005), and "Intellectual Property and Commercial Aspects of Pharmacogenomics," in Pharmacogenomics: Social, Ethical, And Clinical Dimensions, Ed. Mark A. Rothstein (2003). Mr. Brown has an undergraduate degree from Purdue University, and a law degree from Indiana University.
Michael J. Sandel
Michael J. Sandel is the Anne T. and Robert M. Bass Professor of Government at Harvard University, where he has taught political philosophy since 1980. His publications include Liberalism and the Limits of Justice (Cambridge University Press, 1982, 2nd edition, 1997; translated into seven languages), Democracy's Discontent: America in Search of a Public Philosophy (Harvard University Press, 1996), Liberalism and Its Critics (ed., Blackwell, 1984), and articles in scholarly journals, law reviews, and general publications such as The Atlantic Monthly, The New Republic, and The New York Times. Mr. Sandel teaches graduate and undergraduate courses in contemporary political philosophy, including "Ethics and Biotechnology," "Markets, Morals, and Law," and "Globalization and Its Discontents." His undergraduate course, "Justice," has enrolled over 10,000 students, making it one of the most popular courses in Harvard's history. In 1985, he was awarded the Harvard-Radcliff Phi Beta Kappa Teaching Prize, and in 1999 was named a Harvard College Professor in recognition of his contributions to undergraduate teaching. Mr. Sandel has lectured to academic and general audiences in North America, Europe, Japan, India, and Australia. He was a visiting professor at the Sorbonne (Paris) in 2001, and delivered the Tanner Lectures on Human Values at Oxford University in 1998. The recipient of three honorary degrees, he has received fellowships from the Carnegie Corporation, the National Endowment for the Humanities, the Ford Foundation, and the American Council of Learned Societies. He currently serves on the President's Council on Bioethics, a national body appointed by the President to examine the ethical implications of new biomedical technologies. A summa cum laude, Phi Beta Kappa graduate of Brandeis University (1975), Mr. Sandel received his doctorate from Oxford University (D.Phil.,1981), where he was a Rhodes Scholar.
Harris Berman, MD
Harris Berman, MD, is Dean and Morton A. Madoff Professor, Tufts University School of Medicine, Department of Public Health and Family Medicine. An authority in health care financing and organization, he served as CEO of the 900,000-member nonprofit managed care organization Tufts Health Plan from 1986 to 2003. In 1971, he co-founded the Matthew Thornton Health Plan in Nashua, the first HMO in northern New England. A graduate of Harvard College, Dr. Berman received his medical degree at Columbia University College of Physicians and Surgeons, followed by residency training at the Harvard Medical Service of Boston City Hospital and the Tufts-New England Medical Center and an Infectious Disease fellowship at Tufts-New England Medical Center. He is a Fellow of the American College of Physicians. Dr. Berman served as a Peace Corps physician for two years.
James Roosevelt, Jr.
Mr. Roosevelt joined Tufts Health Plan in 1999 as senior vice president and general counsel and held that position until June 2005, when he became president and chief executive officer. As the general counsel, he presided over the legal department and the company’s compliance, privacy and government relations functions.
Before joining Tufts Health Plan, Mr. Roosevelt was the associate commissioner for Retirement Policy for the Social Security Administration in Washington, D.C. He has also served as chief legal counsel for the Massachusetts Democratic Party and is co-chair of the Rules and By-laws Committee of the Democratic National Committee. Mr. Roosevelt spent 10 years as partner at Choate, Hall and Stewart in Boston. He is past chairman of the board of trustees for the Massachusetts Hospital Association, past president of the American Health Lawyers Association and past chairman of the board of trustees for Mount Auburn Hospital.
Mr. Roosevelt received his J.D. from Harvard University Law School and his B.A. with honors in government from Harvard College. He has also completed the Advanced Management Program at Harvard Business School.
